Suppr超能文献

癌症化疗中的口服氟嘧啶类药物。

The oral fluoropyrimidines in cancer chemotherapy.

作者信息

Lamont E B, Schilsky R L

机构信息

Department of Medicine, the Robert Wood Johnson Clinical Scholars Program, University of Chicago, Illinois 60637, USA.

出版信息

Clin Cancer Res. 1999 Sep;5(9):2289-96.

Abstract

A classic example of a rationally developed class of anticancer drugs, the fluoropyrimidines are now the focus of further rational approaches to cancer chemotherapy as they are transformed into oral formulations. Given alone, oral 5-fluorouracil (5-FU) has erratic absorption and nonlinear pharmacokinetics. However, when oral 5-FU is given as a prodrug and/or paired with a dihydropyrimidine dehydrogenase inhibitor, the resultant 5-FU has linear pharmacokinetics that may approximate the less myelosuppressive continuous i.v. infusion schedule of 5-FU administration without the use of infusion catheters and pumps. We review the preclinical and clinical experience of several of the oral fluoropyrimidines.

摘要

氟嘧啶类药物是合理开发的一类抗癌药物的经典例子,随着它们转化为口服制剂,现在已成为癌症化疗进一步合理方法的焦点。单独使用时,口服5-氟尿嘧啶(5-FU)吸收不稳定且药代动力学呈非线性。然而,当口服5-FU作为前药给予和/或与二氢嘧啶脱氢酶抑制剂配对时,所得的5-FU具有线性药代动力学,这可能近似于5-FU给药时骨髓抑制作用较小的持续静脉输注方案,而无需使用输液导管和泵。我们回顾了几种口服氟嘧啶类药物的临床前和临床经验。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验